New drug targets genetic form of Parkinson's in Early-Stage trial
Disease control
Recruiting now
This study tests an experimental drug called NEU-411 in 150 people aged 40-80 with early Parkinson's disease who have a specific genetic profile linked to the LRRK2 pathway. Participants will be randomly assigned to receive either NEU-411 or a placebo for about a year, with an op…
Phase: PHASE2 • Sponsor: Neuron23 Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC